KYNB

Kyntra BIO, Inc.

NasdaqAdd to watchlist

$7.08

−$0.02−0.35%

Delayed · 2026-09-18T20:00:00.000Z · marketstack

Aug 24, 2026$7.08

−$0.91−11.34%over 1M

Session

Day range58% of range

$6.66$7.38

Fundamentals

Visualize fundamentals and more

Market cap: 28.64M
P/E ratio: 0.16

Risk factors, year on year

Item 1AMar 2026 10-KMar 2025

added: 25
dropped: 74
re-drafted: 42

Out of 251 passages in this year’s Item 1A.

New this year

We are substantially dependent on the success of our lead products roxadustat and FG-3246 (in conjunction with our PET (as defined below) imaging agent FG-3180).

98 more passages are on Bespoke

Bespoke Create a free account

Free, no card, and it does not expire. See what the paid plans add

What it says it is exposed to

From Item 1A of its most recent 10-K, filed March 2026.

FDA approval
Data privacy
Litigation
Cybersecurity
China
Product recalls
Reimbursement
Supply chain

And 14 more.

FDA approval
Before obtaining regulatory approval for the commercial sale of any product candidate, we must demonstrate through extensive preclinical trials and clinical trials that the product candidate is effective and has an acceptable safety profile for use in each …

7 more themes are on Measure

Measure Create a free account

Free, no card, and it does not expire. See what the paid plans add

Recent activity

18 more events are on Measure

Measure Create a free account

Free, no card, and it does not expire. See what the paid plans add

Discussion

No comments yet

Set a username to join the discussion. It’s the only thing shown next to what you post, never your email address.

Comments are written by other users. Nothing here is investment advice and nothing is checked for accuracy.

Updated Sep 18, 2026 · the last close

Kyntra BIO, Inc. investor relations

What KYNB has filed with the SEC. This is not Kyntra BIO, Inc.’s own investor relations site: these filings are the primary source that site publishes from.

Where else KYNB appears

KYNB is among the largest companies matching:

Ask about Kyntra BIO, Inc.

The assistant answers from what KYNB has actually filed: 13 annual reports filed with the SEC, 11 Form 4 filings from the last year and 1 fund that holds it. Every figure in a reply links to the filing it came from, so an answer can be checked rather than believed.

Press one and the answer appears right here on the page, from KYNB's filings and figures. One a day without an account; a free account has its own, and no card.

See how much of Kyntra BIO, Inc. each of these investors holds, and every quarter they moved.

Ten seconds. No card. Nothing to cancel.

No card, no broker connection.

Continue with Google

What an account lets you do with Kyntra BIO, Inc.

Be told the moment a KYNB insider trades
Put Kyntra BIO, Inc. on a watchlist for a free alert, the bell and a daily email, when a Form 4 worth a row is filed, with vesting and automatic tax sales already struck out so what lands is a decision, not paperwork.
The full filing historyMeasure
Ask what growth the price is already betting on
Kyntra BIO, Inc.'s income statement, balance sheet and cash flow as filed, and the ratios computed from them, plus a reverse DCF that holds today's price fixed and solves for the growth it requires.
The reverse DCFMeasure
Watch the same stakes the professionals are watching
Every tracked position priced at the quarter it was filed and diffed against the one before it: how big a bet each one is, and by how much it changed.
Every position, sizedMeasure
Interrogate the filing, not the internet
Ask anything about Kyntra BIO, Inc.'s fundamentals. The assistant answers from its own filings and cites the figure, never a guess from the open web.

Create a free account See what the paid plans add

Free, no card, and it does not expire.

What it says it is exposed to

From Item 1A of its most recent 10-K, filed March 2026.

FDA approval
Data privacy
Litigation
Cybersecurity
China
Product recalls
Reimbursement
Supply chain

And 14 more.

FDA approval
Before obtaining regulatory approval for the commercial sale of any product candidate, we must demonstrate through extensive preclinical trials and clinical trials that the product candidate is effective and has an acceptable safety profile for use in each …

7 more themes are on Measure

Measure Create a free account

Free, no card, and it does not expire. See what the paid plans add

Risk factors, year on year

Item 1AMar 2026 10-KMar 2025

added: 25
dropped: 74
re-drafted: 42

Out of 251 passages in this year’s Item 1A.

New this year

We are substantially dependent on the success of our lead products roxadustat and FG-3246 (in conjunction with our PET (as defined below) imaging agent FG-3180).

98 more passages are on Bespoke

Bespoke Create a free account

Free, no card, and it does not expire. See what the paid plans add